Acquired Company

TuHURA Biosciences, Inc. completed the merger with Kintara Therapeutics, Inc. on October 18, 2024, with TuHURA surviving the merger and changing its name to TuHURA Biosciences, Inc.

Kintara Therapeutics, Inc. operates as a clinical and commercial stage drug development company with a focus on the treatment of cancer. The Company focuses on identifying clinical and commercial-stage compounds and establishing a scientific rationale for development in modern orphan drug indications. Kintara Therapeutics serves customers worldwide. Show more

12707 High Bluff Drive, Suite 200, California, 92130, US

www.kintara.com

Polish and Other Sanitation Good Manufacturing

Manufacturing

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$1.11

Open

$1.17

Volume

1,317,307

Day Range

$1.02 - $1.20

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

0.12%

Institutional Own.

1.47%

Qtr Updated

06/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
REM-001 Details Metastatic breast cancer, Cancer	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IFX-Hu2.0 Details Cancer, Metastatic merkel cell carcinoma, Cutaneous squamous cell carcinoma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VAL-083 Details Glioblastoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.